Christopher Fenimore - Regeneron Pharmaceuticals Vice President Controller

REGN Stock  USD 966.30  2.75  0.29%   

President

Mr. Christopher Fenimore is Vice President, Controller of the Company. He was Vice President, Controller since March 2017. From January 2017 to March 2017, he served as Vice President, Deputy Controller, and previously served as Vice President, Financial Planning from January 2012 to December 2016. Prior to joining the Company in 2003, he was Vice President, Finance at Mojave Therapeutics, Inc. Mr. Fenimore prior experience includes working as a supervising senior accountant at KPMG, as well as healthcare industryfocused VC and investment banking roles. Mr. Fenimore holds an M.A. in Biotechnology from Columbia University, an M.B.A. in Professional Accounting from Rutgers Business School, and a B.A. in Economics from Rutgers University. Mr. Fenimore is a Certified Public Accountant in the State of New York. since 2017.
Age 53
Tenure 7 years
Professional MarksMBA
Address 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
Phone914 847 7000
Webhttps://www.regeneron.com
Fenimore holds an M.A. in Biotechnology from Columbia University, an M.B.A. in Professional Accounting from Rutgers Business School, and a B.A. in Economics from Rutgers University.

Regeneron Pharmaceuticals Management Efficiency

The company has return on total asset (ROA) of 0.0849 % which means that it generated a profit of $0.0849 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of 0.1626 %, meaning that it created $0.1626 on every $100 dollars invested by stockholders. Regeneron Pharmaceuticals' management efficiency ratios could be used to measure how well Regeneron Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of the 28th of March 2024, Return On Capital Employed is likely to grow to 0.14. Also, Return On Assets is likely to grow to 0.13. At this time, Regeneron Pharmaceuticals' Net Tangible Assets are very stable compared to the past year. As of the 28th of March 2024, Fixed Asset Turnover is likely to grow to 3.32, while Other Current Assets are likely to drop about 203.9 M.
The company currently holds 2.7 B in liabilities with Debt to Equity (D/E) ratio of 0.13, which may suggest the company is not taking enough advantage from borrowing. Regeneron Pharmaceuticals has a current ratio of 5.25, suggesting that it is liquid enough and is able to pay its financial obligations when due. Debt can assist Regeneron Pharmaceuticals until it has trouble settling it off, either with new capital or with free cash flow. So, Regeneron Pharmaceuticals' shareholders could walk away with nothing if the company can't fulfill its legal obligations to repay debt. However, a more frequent occurrence is when companies like Regeneron Pharmaceuticals sell additional shares at bargain prices, diluting existing shareholders. Debt, in this case, can be an excellent and much better tool for Regeneron to invest in growth at high rates of return. When we think about Regeneron Pharmaceuticals' use of debt, we should always consider it together with cash and equity.

Similar Executives

Found 14 records

PRESIDENT Age

Bruce CFAEquillium
58
Craig PhilipsKineta Inc
63
Patrick KaltenbachAgilent Technologies
53
Alicia RodriguezAgilent Technologies
N/A
Dominique GrauAgilent Technologies
65
Henrik AncherJensenAgilent Technologies
59
Bruce SteelEquillium
50
Michael TangAgilent Technologies
50
Rodney GonsalvesAgilent Technologies
58
Samraat RahaAgilent Technologies
51
Jacob ThaysenAgilent Technologies
49
Eilon AsculaiMediwound
N/A
Robert McMahonAgilent Technologies
55
Mark DoakAgilent Technologies
63
Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company was incorporated in 1988 and is headquartered in Tarrytown, New York. Regeneron Pharmaceuticals operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10915 people. Regeneron Pharmaceuticals (REGN) is traded on NASDAQ Exchange in USA. It is located in 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707 and employs 13,450 people. Regeneron Pharmaceuticals is listed under Biotechnology category by Fama And French industry classification.

Management Performance

Regeneron Pharmaceuticals Leadership Team

Elected by the shareholders, the Regeneron Pharmaceuticals' board of directors comprises two types of representatives: Regeneron Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Regeneron. The board's role is to monitor Regeneron Pharmaceuticals' management team and ensure that shareholders' interests are well served. Regeneron Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Regeneron Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
Charles Baker, Independent Director
Joseph Goldstein, Independent Director
Anthony Coles, Independent Director
Patrice Gilooly, Senior Operations
Christopher CPA, Head Finance
George Sing, Independent Director
Gerald Underwood, Senior Operations
Peter Powchik, Senior Vice President - Clinical Development
Jay Markowitz, Senior Vice President - Portfolio Management
Robert Terifay, Sr. VP of Commercial
Robert Landry, CFO and Sr. VP of Fin.
Michael Brown, Independent Director
Ryan Crowe, Senior Analysis
Christine Poon, Independent Director
Neil Stahl, Executive VP of RandD
Marion McCourt, Senior Vice President and Head of Commercial
George Yancopoulos, Chief Scientific Officer and President - Regeneron Laboratories, Director
Andrew Murphy, Executive Research
Huda Zoghbi, Director
Bonnie Bassler, Director
Joseph LaRosa, Senior Vice President General Counsel, Secretary
Bob McCowan, Senior Officer
Daniel Plew, Senior Vice President General Manager - Industrial Operations and Product Supply
Leonard Schleifer, President CEO, Director
Alfred Gilman, Independent Director
Roy Vagelos, Chairman of the Board
Michael Aberman, Vice President - Strategy
Manisha Narasimhan, IR Contact
Douglas McCorkle, Vice President Controller, Assistant Treasurer
Marc TessierLavigne, Independent Director
Christopher Fenimore, Vice President Controller
Arthur Ryan, Independent Director

Regeneron Stock Performance Indicators

The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Regeneron Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.

Regeneron Pharmaceuticals Investors Sentiment

The influence of Regeneron Pharmaceuticals' investor sentiment on the probability of its price appreciation or decline could be a good factor in your decision-making process regarding taking a position in Regeneron. The overall investor sentiment generally increases the direction of a stock movement in a one-year investment horizon. However, the impact of investor sentiment on the entire stock market does not have solid backing from leading economists and market statisticians.
Investor biases related to Regeneron Pharmaceuticals' public news can be used to forecast risks associated with an investment in Regeneron. The trend in average sentiment can be used to explain how an investor holding Regeneron can time the market purely based on public headlines and social activities around Regeneron Pharmaceuticals. Please note that most equities that are difficult to arbitrage are affected by market sentiment the most.
Regeneron Pharmaceuticals' market sentiment shows the aggregated news analyzed to detect positive and negative mentions from the text and comments. The data is normalized to provide daily scores for Regeneron Pharmaceuticals' and other traded tickers. The bigger the bubble, the more accurate is the estimated score. Higher bars for a given day show more participation in the average Regeneron Pharmaceuticals' news discussions. The higher the estimated score, the more favorable is the investor's outlook on Regeneron Pharmaceuticals.

Regeneron Pharmaceuticals Implied Volatility

    
  25.45  
Regeneron Pharmaceuticals' implied volatility exposes the market's sentiment of Regeneron Pharmaceuticals stock's possible movements over time. However, it does not forecast the overall direction of its price. In a nutshell, if Regeneron Pharmaceuticals' implied volatility is high, the market thinks the stock has potential for high price swings in either direction. On the other hand, the low implied volatility suggests that Regeneron Pharmaceuticals stock will not fluctuate a lot when Regeneron Pharmaceuticals' options are near their expiration.
Some investors attempt to determine whether the market's mood is bullish or bearish by monitoring changes in market sentiment. Unlike more traditional methods such as technical analysis, investor sentiment usually refers to the aggregate attitude towards Regeneron Pharmaceuticals in the overall investment community. So, suppose investors can accurately measure the market's sentiment. In that case, they can use it for their benefit. For example, some tools to gauge market sentiment could be utilized using contrarian indexes, Regeneron Pharmaceuticals' short interest history, or implied volatility extrapolated from Regeneron Pharmaceuticals options trading.

Currently Active Assets on Macroaxis

When determining whether Regeneron Pharmaceuticals offers a strong return on investment in its stock, a comprehensive analysis is essential. The process typically begins with a thorough review of Regeneron Pharmaceuticals' financial statements, including income statements, balance sheets, and cash flow statements, to assess its financial health. Key financial ratios are used to gauge profitability, efficiency, and growth potential of Regeneron Pharmaceuticals Stock. Outlined below are crucial reports that will aid in making a well-informed decision on Regeneron Pharmaceuticals Stock:
Check out Your Equity Center to better understand how to build diversified portfolios, which includes a position in Regeneron Pharmaceuticals. Also, note that the market value of any company could be tightly coupled with the direction of predictive economic indicators such as signals in price.
To learn how to invest in Regeneron Stock, please use our How to Invest in Regeneron Pharmaceuticals guide.
Note that the Regeneron Pharmaceuticals information on this page should be used as a complementary analysis to other Regeneron Pharmaceuticals' statistical models used to find the right mix of equity instruments to add to your existing portfolios or create a brand new portfolio. You can also try the Economic Indicators module to top statistical indicators that provide insights into how an economy is performing.

Complementary Tools for Regeneron Stock analysis

When running Regeneron Pharmaceuticals' price analysis, check to measure Regeneron Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Regeneron Pharmaceuticals is operating at the current time. Most of Regeneron Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Regeneron Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Regeneron Pharmaceuticals' price. Additionally, you may evaluate how the addition of Regeneron Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.
Risk-Return Analysis
View associations between returns expected from investment and the risk you assume
Idea Breakdown
Analyze constituents of all Macroaxis ideas. Macroaxis investment ideas are predefined, sector-focused investing themes
Portfolio Volatility
Check portfolio volatility and analyze historical return density to properly model market risk
Instant Ratings
Determine any equity ratings based on digital recommendations. Macroaxis instant equity ratings are based on combination of fundamental analysis and risk-adjusted market performance
Aroon Oscillator
Analyze current equity momentum using Aroon Oscillator and other momentum ratios
Portfolio Optimization
Compute new portfolio that will generate highest expected return given your specified tolerance for risk
ETFs
Find actively traded Exchange Traded Funds (ETF) from around the world
Portfolio Comparator
Compare the composition, asset allocations and performance of any two portfolios in your account
Is Regeneron Pharmaceuticals' industry expected to grow? Or is there an opportunity to expand the business' product line in the future? Factors like these will boost the valuation of Regeneron Pharmaceuticals. If investors know Regeneron will grow in the future, the company's valuation will be higher. The financial industry is built on trying to define current growth potential and future valuation accurately. All the valuation information about Regeneron Pharmaceuticals listed above have to be considered, but the key to understanding future value is determining which factors weigh more heavily than others.
Quarterly Earnings Growth
(0.03)
Earnings Share
34.78
Revenue Per Share
122.935
Quarterly Revenue Growth
0.006
Return On Assets
0.0849
The market value of Regeneron Pharmaceuticals is measured differently than its book value, which is the value of Regeneron that is recorded on the company's balance sheet. Investors also form their own opinion of Regeneron Pharmaceuticals' value that differs from its market value or its book value, called intrinsic value, which is Regeneron Pharmaceuticals' true underlying value. Investors use various methods to calculate intrinsic value and buy a stock when its market value falls below its intrinsic value. Because Regeneron Pharmaceuticals' market value can be influenced by many factors that don't directly affect Regeneron Pharmaceuticals' underlying business (such as a pandemic or basic market pessimism), market value can vary widely from intrinsic value.
Please note, there is a significant difference between Regeneron Pharmaceuticals' value and its price as these two are different measures arrived at by different means. Investors typically determine if Regeneron Pharmaceuticals is a good investment by looking at such factors as earnings, sales, fundamental and technical indicators, competition as well as analyst projections. However, Regeneron Pharmaceuticals' price is the amount at which it trades on the open market and represents the number that a seller and buyer find agreeable to each party.